Experts discuss real-world BTCE challenges, toxicity monitoring, and evolving pharmacy practice.
Emilie Aschenbrenner, PharmD, BCOP
Advertisement
Articles by Emilie Aschenbrenner, PharmD, BCOP
Key risks, overlooked toxicities, and real-world monitoring strategies for bispecific T-cell engagers.
This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Functional Cure of Hepatitis B Infections Among Patients Coinfected With HIV
2
White Bagging, Brown Bagging, and the Pharmacist Caught in the Middle
3
FDA Expands Casgevy Approval to Children as Young as 2 Years With Sickle Cell Disease or Transfusion-Dependent β-Thalassemia
4
Targeting Aldosterone at Its Source: The Arrival of Baxdrostat for Resistant Hypertension
5